Efficacy of Osimertinib in Patients With Lung Cancer

Efficacy of Osimertinib in Patients With Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06174857

Enrollment

100

Registered

2023-12-18

Start date

2021-01-01

Completion date

2025-09-15

Last updated

2023-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Non-Small Cell Lung Cancer

Brief summary

This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients must be ≥18 years. * Provision of fully informed consent prior to any study specific procedures. * Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology. * According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	3 years	From registration onto that step until death, or censored at the date of last contact.
progression-free survival	3 years	From registration onto that step until death, or censored at the date of last contact.

Countries

China

Contacts

Primary ContactYongchang C Zhang, MD

zhangyongchang@csu.edu.cn+8613873123436

Backup ContactNong Yang, MD

yangnong0217@163.com+8613055193557

Outcome results